For foreign Emerging Stock Board enterprises, ”*- country of incorporation” indicates stocks without par value or with par value other than NT$10, and ”- country of incorporation” indicates stocks with par value of NT$10 per share.
|
Basic information |
Chairman |
President |
Spokesperson |
Telephone |
Address |
ESM Registration Date |
Tom Lin |
Irene Wang |
Irene Wang |
02-87805008 |
36F, No.68, Sec.5, Zhongxiao E. Rd., Xinyi Dist.Taipei City 11065, Taiwan |
2018/10/08 |
Industrycategory |
Key businesses |
Biotechnology and Medical Care |
Lin BioScience is a new drug development company specializing in innovative therapies for unmet medical need. Its pipeline consists of 4 first-in-class drugs (008, 009, 007 and 002) and 2 technology platform (RBP4 and CDC7 platform) aimed at treating diseases in metabolic, ophthalmology, and oncology.
LBS adopts a fast track development strategy as each drug targets both a blockbuster indication and an orphan disease indication. This allows the drug to be approved in a much faster speed while maintaining the great financial upside.
Both 008, an oral therapy for Dry AMD, and 009, an oral therapy for Fatty Liver Disease, are developed from our RBP4 platform. 008 is the most advanced candidate from the US NIH's highly selective Blueprint Program and has obtained Rare Pediatric Disease and Orphan Drug designation from FDA.
007, developed from our CDC7 platform, is a natural cell cycle CDC7 inhibitor targeting a variety of hard to treat cancers such as leukemia and solid tumors. |
Financial data |
Cash flows statement
| Item
|
|
|
Amount(NTD, in thousands) |
Cash flows from operating activities |
|
|
Cash flows from investing activities |
|
|
Cash flows from financing activities |
|
|
Consolidated/Individual balance sheet
|
Current assets |
|
|
Non-current assets |
|
|
Total assets |
|
|
Current liabilities |
|
|
Non-current liabilities |
|
|
Total liabilities |
|
|
Share capital |
|
|
Capital surplus |
|
|
Retained earnings |
|
|
Other equity interest |
|
|
Treasury shares |
|
|
Total equity attributable to owners of parent |
|
|
Non-controlling interests |
|
|
Total equity |
|
|
Book Value per share(NT$) |
|
|
Consolidated/Individual profit and loss statement |
Operating revenue |
|
|
Operating costs |
|
|
Gross profit from operations |
|
|
Operating expenses |
|
|
Net other income (expenses) |
|
|
Net operating income |
|
|
Non-operating income and expenses |
|
|
Profit before tax |
|
|
Tax expense |
|
|
Profit from continuing operations |
|
|
Profit from discontinued operations |
|
|
Profit |
|
|
Other comprehensive income |
|
|
Comprehensive income |
|
|
Basic earnings per share |
|
|
Auditor's report on latest financial statements: auditor's report:
|
Investors may find more detailed information on the company by visiting the Market Observation Post System.。
|
The information disclosed here concerning foreign enterprises consists of amounts provided in consolidated financial statements.
|